Repetitive Transcranial Magnetic Stimulation-Mediated Neuroprotection in the 5xFAD Mouse Model of Alzheimer’s Disease Through GABRG2 and SNAP25 Modulation
Authors:
- 25 July 2024
- journal article
- research article
- Published by Springer Nature in Molecular Neurobiology
- p. 1-27
Abstract
Alzheimer’s disease (AD) is a leading neurodegenerative disorder with substantial impacts on cognition and behavior. Repetitive transcranial magnetic stimulation (rTMS), a non-invasive neuromodulation technique, has been used to treat various neuropsychiatric disorders, but its efficacy in AD has not been thoroughly investigated. This study examines the neuroprotective effects of rTMS in the 5xFAD mouse model of AD, with a particular focus on its modulation of GABAergic neuronal activity via the GABRG2 and SNAP25 proteins. Transcriptomic sequencing of rTMS-treated 5xFAD mice revealed 32 genes influenced by the treatment, among which GABRG2 was identified as a critical modulatory target. Electrophysiological assessments, including whole-cell patch clamp recordings from frontal cortex neurons, demonstrated significant alterations in inhibitory synaptic currents following rTMS. Subsequent experiments involved sh-GABRG2 transduction combined with rTMS treatment (20Hz, 14 days), examining behavioral responses, GABAergic neuron functionality, cortical GABA expression, cerebrospinal fluid GABA concentrations, β-amyloid accumulation, and pro-inflammatory cytokine levels. The results indicated notable improvements in behavioral performance, enhanced functionality of GABAergic neurons, and reductions in β-amyloid deposition and neuroinflammation after rTMS treatment. Further analysis revealed that SNAP25 overexpression could counteract the negative effects of GABRG2 silencing, highlighting the crucial role of SNAP25 downstream of GABRG2 in mediating rTMS’s therapeutic effects in AD. This research highlights rTMS’s potential to modulate synaptic and vesicular transport mechanisms, offering a promising avenue for ameliorating symptoms of AD through neuroprotective pathways.Keywords
Funding Information
- Hebei Medical Science Research Project Plan (20240255, 20240255, 20240255, 20240255, 20240255, 20240255, 20240255, 20240255, 20240255)
- Hebei Provincial Natural Science Foundation Precision Medicine Joint Fund Cultivation Project (H2021206269, H2022206023, H2021206269, H2022206023, H2021206269, H2022206023, H2021206269, H2022206023, H2021206269, H2022206023, H2021206269, H2022206023, H2021206269, H2022206023, H2021206269, H2022206023, H2021206269, H2022206023)
- Scientific Research Projects of Higher Education Institutions in Hebei Province (QN2024035, QN2024035, QN2024035, QN2024035, QN2024035, QN2024035, QN2024035, QN2024035, QN2024035)
This publication has 66 references indexed in Scilit:
- Alzheimer’s disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugsBiochemical Pharmacology, 2023
- Efficacy and safety of simultaneous rTMS–tDCS over bilateral angular gyrus on neuropsychiatric symptoms in patients with moderate Alzheimer's disease: A prospective, randomized, sham-controlled pilot studyBrain Stimulation, 2022
- Neuromodulation for Chronic Daily HeadacheCurrent Pain and Headache Reports, 2022
- RNA sequencing and its applications in cancer and rare diseasesMolecular Biology Reports, 2022
- Cortical plasticity is correlated with cognitive improvement in Alzheimer’s disease patients after rTMS treatmentBrain Stimulation, 2021
- Interleukin-1β, interleukin-6, and interleukin-17A as indicators reflecting clinical response to celecoxib in ankylosing spondylitis patientsIrish Journal of Medical Science (1971 -), 2020
- Erbin in Amygdala Parvalbumin-Positive Neurons Modulates Anxiety-like BehaviorsBiological Psychiatry, 2020
- Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018)Clinical Neurophysiology, 2020
- Repetitive transcranial magnetic stimulation for cognitive impairment in Alzheimer's disease: a meta-analysis of randomized controlled trialsJournal of Neurology, 2019
- Identification of the molecular subgroups in coronary artery disease by gene expression profilesJournal of Cellular Physiology, 2019